Weight loss drug could be key to stopping breast Cancer's return
NCT ID NCT06517212
Summary
This study is testing if adding the weight loss medication tirzepatide to standard hormone therapy can help prevent breast cancer from spreading in overweight patients. It focuses on people with early-stage, hormone-positive breast cancer who have a high risk of recurrence, as shown by a special blood test. The main goal is to see if weight loss from the drug helps clear cancer markers from the blood and keeps the cancer from spreading to other parts of the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.